22Nd Century - XXII STOCK NEWS

22nd Century Group (NYSE American: XXII) announced significant advancements in its testing capabilities, estimating a 90% reduction in costs and a turnaround time improvement from weeks to hours for its VLN® reduced nicotine tobacco products. The new in-house laboratory will enhance product quality and testing consistency while supporting the anticipated demand for VLN® cigarettes. In preparation for the FDA's Modified Risk Tobacco Product (MRTP) application, the company aims for ISO/IEC 17025 accreditation, demonstrating its commitment to high-quality testing standards.

22nd Century Group has expanded its partnership with KeyGene to enhance research on valuable hemp/cannabis varieties and other plant franchises. This agreement aims to accelerate the development of new plant lines across three franchises, with a focus on commercializing intellectual property in two years. The collaboration supports gene modification and molecular breeding, aiming to create unique cannabinoid traits. Additionally, the partnership is expected to help secure four of the five key partnerships needed in the cannabinoid value chain, positioning XXII for substantial market opportunities.

22nd Century Group has praised the FDA's decision to initiate the rulemaking process to ban menthol in cigarettes, marking a significant step towards reducing addiction and youth smoking. The company anticipates further advancements in nicotine regulation, with the FDA expected to propose a nicotine cap soon. 22nd Century is close to obtaining Modified Risk Tobacco Product (MRTP) authorization for its reduced nicotine content cigarettes, vital for helping current smokers transition away from traditional menthol cigarettes. The company aims to address tobacco-related health disparities through its innovative products.

22nd Century Group, Inc. (NYSE American: XXII) supports Congresswoman Gwen Moore's call to the federal government for legislation to reduce nicotine levels in cigarettes to minimally or non-addictive levels. The company is ready to deliver its VLN® reduced nicotine content cigarette in alignment with FDA proposals. VLN® offers 95% less nicotine than traditional cigarettes. The company aims to address health disparities among minority communities, with high smoking rates especially among low-income African-Americans. 22nd Century believes it is close to obtaining a Modified Risk Tobacco Product designation from the FDA.

22nd Century Group (NYSE American: XXII) has provided over 31 million variable nicotine content research cigarettes for independent studies, supporting the FDA's proposed mandate to reduce nicotine levels in U.S. cigarettes. The company fulfilled a recent order of 3.6 million research cigarettes, demonstrating substantial public health benefits from reduced nicotine content (RNC) products, like their VLN® cigarettes, which contain 95% less nicotine. 22nd Century is poised to supply its VLN® cigarettes upon FDA authorization, aiming to enhance public health and reduce smoking addiction.

22nd Century Group, Inc. (NYSE American: XXII) will host a live audio webcast on May 6, 2021, at 10:00 AM ET to discuss its first quarter 2021 results, which will be released at 6:00 AM ET the same day. CEO James A. Mish and other executives will outline the company's performance and strategic priorities in the tobacco, hemp/cannabis, and a new plant-based franchise market worth over $1.3 trillion. The session will also include a Q&A segment for analysts and investors. Access to the webcast will be available on the company’s Investor Relations webpage.

22nd Century Group, Inc. (NYSE American: XXII) has expressed confidence in the approval of its Modified Risk Tobacco Product (MRTP) application for VLN® cigarettes, which contain 95% less nicotine. The company's letter to shareholders highlights a significant market opportunity, given the global tobacco market's worth of over $800 billion. With 60% of smokers likely to use VLN®, 22nd Century is poised to introduce this product within 90 days of FDA authorization. The firm also aims to innovate within hemp/cannabis, targeting a market projected to exceed $100 billion by 2024.

22nd Century Group (NYSE American: XXII) is poised to launch its VLN® reduced nicotine content cigarettes in collaboration with the FDA. This initiative aligns with the Biden Administration's focus on public health, potentially aiding 5 million smokers to quit and preventing new smokers. Their reduced nicotine cigarettes contain 95% less nicotine than traditional cigarettes, with studies backing their effectiveness. The company is ready to license this technology to other manufacturers, aiming to reduce cigarette addiction and save lives.

22nd Century Group, Inc. (XXII) supports New Zealand's proposal to reduce nicotine in cigarettes to minimal levels, aiming for a smoke-free nation by 2025. The company, known for its reduced nicotine content (RNC) cigarettes, is prepared to aid in this initiative, believing it aligns with public health goals. The firm expects significant global interest in nicotine reduction as New Zealand leads the way, with a focus on aiding smokers to quit. With FDA authorization of their PMTA for RNC cigarettes, 22nd Century is ready to supply the New Zealand market, enhancing its potential for growth in tobacco harm reduction.